Zydus Pharma has launched Topiramate extended-release capsules. The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate extended-release capsules, USP 25 mg, 50 mg and 100 mg, a company statement notified.
It also informed that Zydus is the first company to receive final approval and launch Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg in the US.
The capsule is indicated for epilepsy: initial monotherapy in patients six years of age and older with partial onset or primary generalised tonic-clonic seizures; adjunctive therapy in patients six years of age and older with partial onset, primary generalised tonic-clonic seizures, or seizures associated with Lenox-Gastaut Syndrome (LGS). It is also indicated for prophylaxis of migraine in patients 12 years of age and older, the statement added.
Very good blog post. I definitely love this website. Thanks!